1
|
Koraboina CP, Maddipati VC, Annadurai N, Gurská S, Džubák P, Hajdúch M, Das V, Gundla R. Synthesis and Biological Evaluation of Oxindole Sulfonamide Derivatives as Bruton's Tyrosine Kinase Inhibitors. ChemMedChem 2024; 19:e202300511. [PMID: 37916435 DOI: 10.1002/cmdc.202300511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Revised: 10/26/2023] [Accepted: 11/01/2023] [Indexed: 11/03/2023]
Abstract
Bruton's tyrosine kinase (BTK) is a promising molecular target for several human B-cell-related autoimmune disorders, inflammation, and haematological malignancies. The pathogenic alterations in various cancer tissues depend on mutant BTK for cell proliferation and survival, and BTK is also overexpressed in a range of hematopoietic cells. Due to this, BTK is emerging as a potential drug target to treat various human diseases, and several reversible and irreversible inhibitors have been developed and are being developed. As a result, BTK inhibition, clinically validated as an anticancer treatment, is finding great interest in B-cell malignancies and solid tumours. This study focuses on the design and synthesis of new oxindole sulfonamide derivatives as promising inhibitors of BTK with negligible off-target effects. The most cytotoxic compounds with greater basicity were PID-4 (2.29±0.52 μM), PID-6 (9.37±2.47 μM), and PID-19 (2.64±0.88 μM). These compounds caused a selective inhibition of Burkitt's lymphoma RAMOS cells without significant cytotoxicity in non-BTK cancerous and non-cancerous cell lines. Further, PID-4 showed promising activity in inhibiting BTK and downstream signalling cascades. As a potent inhibitor of Burkitt's lymphoma cells, PID-4 is a promising lead for developing novel chemotherapeutics.
Collapse
Affiliation(s)
- Chandra Prakash Koraboina
- Department of Chemistry, School of Science, GITAM (Deemed to be University), Hyderabad, Telangana, 502 329, India
| | | | - Narendran Annadurai
- Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic
| | - Soňa Gurská
- Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic
- Czech Advanced Technologies and Research Institute (CATRIN), Institute of Molecular and Translational Medicine, Palacký University Olomouc, Křížkovského 511/8, 77900, Olomouc, Czech Republic
| | - Petr Džubák
- Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic
- Czech Advanced Technologies and Research Institute (CATRIN), Institute of Molecular and Translational Medicine, Palacký University Olomouc, Křížkovského 511/8, 77900, Olomouc, Czech Republic
| | - Marián Hajdúch
- Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic
- Czech Advanced Technologies and Research Institute (CATRIN), Institute of Molecular and Translational Medicine, Palacký University Olomouc, Křížkovského 511/8, 77900, Olomouc, Czech Republic
| | - Viswanath Das
- Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Hněvotínská 1333/5, 77900, Olomouc, Czech Republic
- Czech Advanced Technologies and Research Institute (CATRIN), Institute of Molecular and Translational Medicine, Palacký University Olomouc, Křížkovského 511/8, 77900, Olomouc, Czech Republic
| | - Rambabu Gundla
- Department of Chemistry, School of Science, GITAM (Deemed to be University), Hyderabad, Telangana, 502 329, India
| |
Collapse
|
2
|
Faust A, Bäumer N, Schlütermann A, Becht M, Greune L, Geyer C, Rüter C, Margeta R, Wittmann L, Dersch P, Lenz G, Berdel WE, Bäumer S. Tumorzellspezifisches Targeting von Ibrutinib: Einführung von elektrostatischen Antikörper‐Inhibitor‐Konjugaten (AiCs). Angew Chem Int Ed Engl 2022. [DOI: 10.1002/ange.202109769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Andreas Faust
- European Institute for Molecular Imaging Universität Münster Waldeyerstr. 15 48159 Münster Deutschland
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Universität Münster Albert-Schweitzer Campus 1 48149 Münster Deutschland
| | - Nicole Bäumer
- Medizinische Klinik A, Hämatologie/Onkologie Universitätsklinikum Münster Albert-Schweitzer Campus 1 48149 Münster Deutschland
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Universität Münster Albert-Schweitzer Campus 1 48149 Münster Deutschland
| | - Alina Schlütermann
- Medizinische Klinik A, Hämatologie/Onkologie Universitätsklinikum Münster Albert-Schweitzer Campus 1 48149 Münster Deutschland
| | - Manuel Becht
- Medizinische Klinik A, Hämatologie/Onkologie Universitätsklinikum Münster Albert-Schweitzer Campus 1 48149 Münster Deutschland
| | - Lilo Greune
- Institut für Infektiologie Zentrum für Molekulare Biologie der Entzündung (ZMBE) Universität Münster Von-Esmarch-Str. 56 48149 Münster Deutschland
| | - Christiane Geyer
- Institut für Klinische Radiologie Universitätsklinikum Münster Albert-Schweitzer Campus 1 48149 Münster Deutschland
| | - Christian Rüter
- Institut für Infektiologie Zentrum für Molekulare Biologie der Entzündung (ZMBE) Universität Münster Von-Esmarch-Str. 56 48149 Münster Deutschland
| | - Renato Margeta
- European Institute for Molecular Imaging Universität Münster Waldeyerstr. 15 48159 Münster Deutschland
| | - Lisa Wittmann
- Medizinische Klinik A, Hämatologie/Onkologie Universitätsklinikum Münster Albert-Schweitzer Campus 1 48149 Münster Deutschland
| | - Petra Dersch
- Institut für Infektiologie Zentrum für Molekulare Biologie der Entzündung (ZMBE) Universität Münster Von-Esmarch-Str. 56 48149 Münster Deutschland
| | - Georg Lenz
- Medizinische Klinik A, Hämatologie/Onkologie Universitätsklinikum Münster Albert-Schweitzer Campus 1 48149 Münster Deutschland
| | - Wolfgang E. Berdel
- Medizinische Klinik A, Hämatologie/Onkologie Universitätsklinikum Münster Albert-Schweitzer Campus 1 48149 Münster Deutschland
| | - Sebastian Bäumer
- Medizinische Klinik A, Hämatologie/Onkologie Universitätsklinikum Münster Albert-Schweitzer Campus 1 48149 Münster Deutschland
- Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Universität Münster Albert-Schweitzer Campus 1 48149 Münster Deutschland
| |
Collapse
|
3
|
Faust A, Bäumer N, Schlütermann A, Becht M, Greune L, Geyer C, Rüter C, Margeta R, Wittmann L, Dersch P, Lenz G, Berdel WE, Bäumer S. Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs). Angew Chem Int Ed Engl 2021; 61:e202109769. [PMID: 34725904 PMCID: PMC9299256 DOI: 10.1002/anie.202109769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Indexed: 11/12/2022]
Abstract
Ibrutinib is an inhibitor of Bruton's tyrosine kinase that has been approved for the treatment of patients with chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom's macroglobulinemia and is connected with toxicities. To minimize its toxicities, we linked ibrutinib to a cell‐targeted, internalizing antibody. To this end, we synthesized a poly‐anionic derivate, ibrutinib‐Cy3.5, that retains full functionality. This anionic inhibitor is complexed by our anti‐CD20‐protamine targeting conjugate and free protamine, and thereby spontaneously assembles into an electrostatically stabilized vesicular nanocarrier. The complexation led to an accumulation of the drug driven by the CD20 antigen internalization to the intended cells and an amplification of its pharmacological effectivity. In vivo, we observed a significant enrichment of the drug in xenograft lymphoma tumors in immune‐compromised mice and a significantly better response to lower doses compared to the original drug.
Collapse
Affiliation(s)
- Andreas Faust
- European Institute for Molecular Imaging, University of Münster, Waldeyerstr. 15, 48159, Münster, Germany.,Interdisciplinary Center of Clinical Research (IZKF), University of Münster, Albert-Schweitzer Campus 1, 48149, Münster, Germany
| | - Nicole Bäumer
- Department of Medicine A, Hematology/Oncology, University Hospital Münster, Albert-Schweitzer Campus 1, 48149, Muenster, Germany.,Interdisciplinary Center of Clinical Research (IZKF), University of Münster, Albert-Schweitzer Campus 1, 48149, Münster, Germany
| | - Alina Schlütermann
- Department of Medicine A, Hematology/Oncology, University Hospital Münster, Albert-Schweitzer Campus 1, 48149, Muenster, Germany
| | - Manuel Becht
- Department of Medicine A, Hematology/Oncology, University Hospital Münster, Albert-Schweitzer Campus 1, 48149, Muenster, Germany
| | - Lilo Greune
- Institute for Infectiology, Center for Molecular Biology of Inflammation (ZMBE), University of Münster, Von-Esmarch-Str. 56, 48149, Münster, Germany
| | - Christiane Geyer
- Institute for Clinical Radiology, University Hospital Münster, Albert-Schweitzer Campus 1, 48149, Münster, Germany
| | - Christian Rüter
- Institute for Infectiology, Center for Molecular Biology of Inflammation (ZMBE), University of Münster, Von-Esmarch-Str. 56, 48149, Münster, Germany
| | - Renato Margeta
- European Institute for Molecular Imaging, University of Münster, Waldeyerstr. 15, 48159, Münster, Germany
| | - Lisa Wittmann
- Department of Medicine A, Hematology/Oncology, University Hospital Münster, Albert-Schweitzer Campus 1, 48149, Muenster, Germany
| | - Petra Dersch
- Institute for Infectiology, Center for Molecular Biology of Inflammation (ZMBE), University of Münster, Von-Esmarch-Str. 56, 48149, Münster, Germany
| | - Georg Lenz
- Department of Medicine A, Hematology/Oncology, University Hospital Münster, Albert-Schweitzer Campus 1, 48149, Muenster, Germany
| | - Wolfgang E Berdel
- Department of Medicine A, Hematology/Oncology, University Hospital Münster, Albert-Schweitzer Campus 1, 48149, Muenster, Germany
| | - Sebastian Bäumer
- Department of Medicine A, Hematology/Oncology, University Hospital Münster, Albert-Schweitzer Campus 1, 48149, Muenster, Germany.,Interdisciplinary Center of Clinical Research (IZKF), University of Münster, Albert-Schweitzer Campus 1, 48149, Münster, Germany
| |
Collapse
|
4
|
Abstract
Fluorescent dyes attached to kinase inhibitors (KIs) can be used to probe kinases in vitro, in cells, and in vivo. Ideal characteristics of the dyes vary with their intended applications. Fluorophores used in vitro may inform on kinase active site environments, hence the dyes used should be small and have minimal impact on modes of binding. These probes may have short wavelength emissions since blue fluorophores are perfectly adequate in this context. Thus, for instance, KI fragments that mimic nucleobases may be modified to be fluorescent with minimal perturbation to the kinase inhibitor structure. However, progressively larger dyes, that emit at longer wavelengths, are required for cellular and in vivo work. In cells, it is necessary to have emissions above autofluorescence of biomolecules, and near infrared dyes are needed to enable excitation and observation through tissue in vivo. This review is organized to describe probes intended for applications in vitro, in cells, then in vivo. The readers will observe that the probes featured tend to become larger and responsive to the near infared end of the spectrum as the review progresses. Readers may also be surprised to realize that relatively few dyes have been used for fluorophore-kinase inhibitor conjugates, and the area is open for innovations in the types of fluorophores used.
Collapse
Affiliation(s)
- Syed Muhammad Usama
- Department of Chemistry, Texas A&M University, Box 30012, College Station, TX 77842, USA.
| | | | | |
Collapse
|
5
|
Mudasani G, Paidikondala K, Gurská S, Maddirala SJ, Džubák P, Das V, Gundla R. C‐5 Aryl Substituted Azaspirooxindolinones Derivatives: Synthesis and Biological Evaluation as Potential Inhibitors of Tec Family Kinases. European J Org Chem 2021. [DOI: 10.1002/ejoc.202100699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Gopal Mudasani
- Department of Chemistry, School of Science GITAM (Deemed to be University) Hyderabad 502102 Telangana India
- Medicinal Chemistry Laboratory Division AragenLifesciences Pvt. Ltd Survey No: 125(Part) & 126, IDA Mallapur Hyderabad 500 076 India
| | - Kalyani Paidikondala
- Department of Chemistry, School of Science GITAM (Deemed to be University) Hyderabad 502102 Telangana India
| | - Soňa Gurská
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry Czech Advanced Technology and Research Institute Palacký University Olomouc Hněvotínská 1333/5 77900 Olomouc Czech Republic
| | - Shambabu Joseph Maddirala
- Medicinal Chemistry Laboratory Division AragenLifesciences Pvt. Ltd Survey No: 125(Part) & 126, IDA Mallapur Hyderabad 500 076 India
| | - Petr Džubák
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry Czech Advanced Technology and Research Institute Palacký University Olomouc Hněvotínská 1333/5 77900 Olomouc Czech Republic
| | - Viswanath Das
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry Czech Advanced Technology and Research Institute Palacký University Olomouc Hněvotínská 1333/5 77900 Olomouc Czech Republic
| | - Rambabu Gundla
- Department of Chemistry, School of Science GITAM (Deemed to be University) Hyderabad 502102 Telangana India
| |
Collapse
|
6
|
Li YH, Li XX, Hong JJ, Wang YX, Fu JB, Yang H, Yu CY, Li FC, Hu J, Xue WW, Jiang YY, Chen YZ, Zhu F. Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs. Brief Bioinform 2021; 21:649-662. [PMID: 30689717 PMCID: PMC7299286 DOI: 10.1093/bib/bby130] [Citation(s) in RCA: 106] [Impact Index Per Article: 35.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Revised: 11/01/2018] [Accepted: 11/02/2018] [Indexed: 12/14/2022] Open
Abstract
Drugs produce their therapeutic effects by modulating specific targets, and there are 89 innovative targets of first-in-class drugs approved in 2004–17, each with information about drug clinical trial dated back to 1984. Analysis of the clinical trial timelines of these targets may reveal the trial-speed differentiating features for facilitating target assessment. Here we present a comprehensive analysis of all these 89 targets, following the earlier studies for prospective prediction of clinical success of the targets of clinical trial drugs. Our analysis confirmed the literature-reported common druggability characteristics for clinical success of these innovative targets, exposed trial-speed differentiating features associated to the on-target and off-target collateral effects in humans and further revealed a simple rule for identifying the speedy human targets through clinical trials (from the earliest phase I to the 1st drug approval within 8 years). This simple rule correctly identified 75.0% of the 28 speedy human targets and only unexpectedly misclassified 13.2% of 53 non-speedy human targets. Certain extraordinary circumstances were also discovered to likely contribute to the misclassification of some human targets by this simple rule. Investigation and knowledge of trial-speed differentiating features enable prioritized drug discovery and development.
Collapse
Affiliation(s)
- Ying Hong Li
- Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.,Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China
| | - Xiao Xu Li
- Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.,Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China
| | - Jia Jun Hong
- Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
| | - Yun Xia Wang
- Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
| | - Jian Bo Fu
- Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
| | - Hong Yang
- Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China
| | - Chun Yan Yu
- Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China
| | - Feng Cheng Li
- Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
| | - Jie Hu
- School of International Studies, Zhejiang University, Hangzhou, China
| | - Wei Wei Xue
- Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China
| | - Yu Yang Jiang
- State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen, Guangdong, China
| | - Yu Zong Chen
- Bioinformatics and Drug Design Group, Department of Pharmacy, National University of Singapore, Singapore, Singapore
| | - Feng Zhu
- Lab of Innovative Drug Research and Bioinformatics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.,Innovative Drug Research and Bioinformatics Group, School of Pharmaceutical Sciences and Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China
| |
Collapse
|
7
|
Wilkovitsch M, Haider M, Sohr B, Herrmann B, Klubnick J, Weissleder R, Carlson JCT, Mikula H. A Cleavable C 2-Symmetric trans-Cyclooctene Enables Fast and Complete Bioorthogonal Disassembly of Molecular Probes. J Am Chem Soc 2020; 142:19132-19141. [PMID: 33119297 PMCID: PMC7662912 DOI: 10.1021/jacs.0c07922] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Indexed: 12/15/2022]
Abstract
Bioorthogonal chemistry is bridging the divide between static chemical connectivity and the dynamic physiologic regulation of molecular state, enabling in situ transformations that drive multiple technologies. In spite of maturing mechanistic understanding and new bioorthogonal bond-cleavage reactions, the broader goal of molecular ON/OFF control has been limited by the inability of existing systems to achieve both fast (i.e., seconds to minutes, not hours) and complete (i.e., >99%) cleavage. To attain the stringent performance characteristics needed for high fidelity molecular inactivation, we have designed and synthesized a new C2-symmetric trans-cyclooctene linker (C2TCO) that exhibits excellent biological stability and can be rapidly and completely cleaved with functionalized alkyl-, aryl-, and H-tetrazines, irrespective of click orientation. By incorporation of C2TCO into fluorescent molecular probes, we demonstrate highly efficient extracellular and intracellular bioorthogonal disassembly via omnidirectional tetrazine-triggered cleavage.
Collapse
Affiliation(s)
- Martin Wilkovitsch
- Institute
of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria
| | - Maximilian Haider
- Institute
of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria
| | - Barbara Sohr
- Institute
of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria
| | - Barbara Herrmann
- Institute
of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria
| | - Jenna Klubnick
- Center
for Systems Biology, Massachusetts General
Hospital Research Institute, Boston, Massachusetts 02114, United States
| | - Ralph Weissleder
- Center
for Systems Biology, Massachusetts General
Hospital Research Institute, Boston, Massachusetts 02114, United States
- Department
of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Jonathan C. T. Carlson
- Center
for Systems Biology, Massachusetts General
Hospital Research Institute, Boston, Massachusetts 02114, United States
- Cancer
Center, Massachusetts General Hospital and
Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Hannes Mikula
- Institute
of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9, 1060 Vienna, Austria
| |
Collapse
|
8
|
Vinegoni C, Feruglio PF, Gryczynski I, Mazitschek R, Weissleder R. Fluorescence anisotropy imaging in drug discovery. Adv Drug Deliv Rev 2019; 151-152:262-288. [PMID: 29410158 PMCID: PMC6072632 DOI: 10.1016/j.addr.2018.01.019] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Revised: 01/29/2018] [Accepted: 01/30/2018] [Indexed: 12/15/2022]
Abstract
Non-invasive measurement of drug-target engagement can provide critical insights in the molecular pharmacology of small molecule drugs. Fluorescence polarization/fluorescence anisotropy measurements are commonly employed in protein/cell screening assays. However, the expansion of such measurements to the in vivo setting has proven difficult until recently. With the advent of high-resolution fluorescence anisotropy microscopy it is now possible to perform kinetic measurements of intracellular drug distribution and target engagement in commonly used mouse models. In this review we discuss the background, current advances and future perspectives in intravital fluorescence anisotropy measurements to derive pharmacokinetic and pharmacodynamic measurements in single cells and whole organs.
Collapse
Affiliation(s)
- Claudio Vinegoni
- Center for System Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
| | - Paolo Fumene Feruglio
- Center for System Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Neurological, Biomedical and Movement Sciences, University of Verona, Verona, Italy
| | - Ignacy Gryczynski
- University of North Texas Health Science Center, Institute for Molecular Medicine, Fort Worth, TX, United States
| | - Ralph Mazitschek
- Center for System Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Ralph Weissleder
- Center for System Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| |
Collapse
|
9
|
Li R, Attari A, Prytyskach M, Garlin MA, Weissleder R, Miller MA. Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics. Cytometry A 2019; 97:528-539. [PMID: 31423731 DOI: 10.1002/cyto.a.23872] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Revised: 07/16/2019] [Accepted: 07/22/2019] [Indexed: 12/17/2022]
Abstract
Cell-to-cell heterogeneity can substantially impact drug response, especially for monoclonal antibody (mAb) therapies that may exhibit variability in both delivery (pharmacokinetics) and action (pharmacodynamics) within solid tumors. However, it has traditionally been difficult to examine the kinetics of mAb delivery at a single-cell level and in a manner that enables controlled dissection of target-dependent and -independent behaviors. To address this issue, here we developed an in vivo confocal (intravital) microscopy approach to study single-cell mAb pharmacology in a mosaic xenograft comprising a mixture of cancer cells with variable expression of the receptor HER2. As a proof-of-principle, we applied this model to trastuzumab therapy, a HER2-targeted mAb widely used for treating breast and gastric cancer patients. Trastuzumab accumulated to a higher degree in HER2-over expressing tumor cells compared to HER2-low tumor cells (~5:1 ratio at 24 h after administration) but importantly, the majority actually accumulated in tumor-associated phagocytes. For example, 24 h after IV administration over 50% of tumoral trastuzumab was found in phagocytes whereas at 48 h it was >80%. Altogether, these results reveal the dynamics of how phagocytes influence mAb behavior in vivo, and demonstrate an application of intravital microscopy for quantitative single-cell measurement of mAb distribution and retention in tumors with heterogeneous target expression. © 2019 International Society for Advancement of Cytometry.
Collapse
Affiliation(s)
- Ran Li
- Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts
| | - Adel Attari
- Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts
| | - Mark Prytyskach
- Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts
| | - Michelle A Garlin
- Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts
| | - Ralph Weissleder
- Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.,Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.,Department of Systems Biology, Harvard Medical School, Boston, Massachusetts
| | - Miles A Miller
- Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.,Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
10
|
Hilpert LJ, Sieger SV, Haydl AM, Breit B. Palladium‐ and Rhodium‐Catalyzed Dynamic Kinetic Resolution of Racemic Internal Allenes Towards Chiral Pyrazoles. Angew Chem Int Ed Engl 2019; 58:3378-3381. [DOI: 10.1002/anie.201812984] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Indexed: 11/12/2022]
Affiliation(s)
- Lukas J. Hilpert
- Institut für Organische ChemieAlbert-Ludwigs-Universität Freiburg Albertstraße 21 79104 Freiburg im Breisgau Germany
| | - Simon V. Sieger
- Institut für Organische ChemieAlbert-Ludwigs-Universität Freiburg Albertstraße 21 79104 Freiburg im Breisgau Germany
| | - Alexander M. Haydl
- Institut für Organische ChemieAlbert-Ludwigs-Universität Freiburg Albertstraße 21 79104 Freiburg im Breisgau Germany
| | - Bernhard Breit
- Institut für Organische ChemieAlbert-Ludwigs-Universität Freiburg Albertstraße 21 79104 Freiburg im Breisgau Germany
| |
Collapse
|
11
|
Bensinger D, Stubba D, Cremer A, Kohl V, Waßmer T, Stuckert J, Engemann V, Stegmaier K, Schmitz K, Schmidt B. Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations. J Med Chem 2019; 62:2428-2446. [PMID: 30742435 DOI: 10.1021/acs.jmedchem.8b01714] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The use of covalent irreversible binding inhibitors is an established concept for drug development. Usually, the discovery of new irreversible kinase inhibitors occurs serendipitously, showing that efficient rational approaches for the rapid discovery of new drugs are needed. Herein, we report a virtual screening strategy that led to the discovery of irreversible inhibitors of FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia. A virtual screening library was designed to target the highly conserved Cys828 residue preceding the DFG motif by modification of reported reversible inhibitors with chemically reactive groups. Prospective covalent docking allowed the identification of two lead series, resulting in a massive increase in inhibition of kinase activity and cell viability by irreversible inhibitors compared to the corresponding reversible scaffolds. Lead compound 4b (BSc5371) displays superior cytotoxicity in FLT3-dependent cell lines to compounds in recent clinical trials and overcomes drug-resistant mutations.
Collapse
Affiliation(s)
- Dennis Bensinger
- Clemens-Schöpf-Institute for Organic Chemistry and Biochemistry , Technische Universität Darmstadt , 64287 Darmstadt , Germany
| | - Daniel Stubba
- Clemens-Schöpf-Institute for Organic Chemistry and Biochemistry , Technische Universität Darmstadt , 64287 Darmstadt , Germany
| | - Anjali Cremer
- Department of Pediatric Oncology, Dana-Farber Cancer Institute , Harvard Medical School , Boston , Massachusetts 02215 , United States
| | - Vanessa Kohl
- Clemens-Schöpf-Institute for Organic Chemistry and Biochemistry , Technische Universität Darmstadt , 64287 Darmstadt , Germany
| | - Theresa Waßmer
- Clemens-Schöpf-Institute for Organic Chemistry and Biochemistry , Technische Universität Darmstadt , 64287 Darmstadt , Germany
| | - Johanna Stuckert
- Clemens-Schöpf-Institute for Organic Chemistry and Biochemistry , Technische Universität Darmstadt , 64287 Darmstadt , Germany
| | - Victoria Engemann
- Clemens-Schöpf-Institute for Organic Chemistry and Biochemistry , Technische Universität Darmstadt , 64287 Darmstadt , Germany
| | - Kimberly Stegmaier
- Department of Pediatric Oncology, Dana-Farber Cancer Institute , Harvard Medical School , Boston , Massachusetts 02215 , United States
| | - Katja Schmitz
- Clemens-Schöpf-Institute for Organic Chemistry and Biochemistry , Technische Universität Darmstadt , 64287 Darmstadt , Germany
| | - Boris Schmidt
- Clemens-Schöpf-Institute for Organic Chemistry and Biochemistry , Technische Universität Darmstadt , 64287 Darmstadt , Germany
| |
Collapse
|
12
|
Qiu H, Caldwell R, Liu-Bujalski L, Goutopoulos A, Jones R, Potnick J, Sherer B, Bender A, Grenningloh R, Xu D, Gardberg A, Mochalkin I, Johnson T, Viacava Follis A, Head J, Morandi F. Discovery of Affinity-Based Probes for Btk Occupancy Assays. ChemMedChem 2019; 14:217-223. [DOI: 10.1002/cmdc.201800714] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Indexed: 01/08/2023]
Affiliation(s)
- Hui Qiu
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Richard Caldwell
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Lesley Liu-Bujalski
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Andreas Goutopoulos
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Reinaldo Jones
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Justin Potnick
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Brian Sherer
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Andrew Bender
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Roland Grenningloh
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Daigen Xu
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Anna Gardberg
- Constellation Pharmaceuticals; 215 First Street, Suite 200 Cambridge MA 02142 USA
| | - Igor Mochalkin
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Theresa Johnson
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Ariele Viacava Follis
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Jared Head
- EMD Serono Research & Development Institute; 45A Middlesex Turnpike Billerica MA 01821 USA
| | - Federica Morandi
- Cellular Enzymology; F. Hoffmann-La Roche AG; Konzern-Hauptsitz; Grenzacherstrasse 124 4070 Basel Switzerland
| |
Collapse
|
13
|
Wang X, Ma N, Wu R, Ding K, Li Z. A novel reactive turn-on probe capable of selective profiling and no-wash imaging of Bruton's tyrosine kinase in live cells. Chem Commun (Camb) 2019; 55:3473-3476. [DOI: 10.1039/c9cc01059a] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A series of reaction-based probes have been developed by conjugation of maleimide–coumarin into ibrutinib. The resulting probes display high sensitivity and selectivity toward BTK, and were proven to be suitable for simultaneous protein labeling and no-wash imaging of BTK inside live mammalian cells.
Collapse
Affiliation(s)
- Xin Wang
- School of Pharmacy
- Jinan University
- Guangzhou City Key Laboratory of Precision Chemical Drug Development
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development
- Ministry of Education (MOE) of People's Republic of China
| | - Nan Ma
- School of Pharmacy
- Jinan University
- Guangzhou City Key Laboratory of Precision Chemical Drug Development
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development
- Ministry of Education (MOE) of People's Republic of China
| | - Rui Wu
- School of Pharmacy
- Jinan University
- Guangzhou City Key Laboratory of Precision Chemical Drug Development
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development
- Ministry of Education (MOE) of People's Republic of China
| | - Ke Ding
- School of Pharmacy
- Jinan University
- Guangzhou City Key Laboratory of Precision Chemical Drug Development
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development
- Ministry of Education (MOE) of People's Republic of China
| | - Zhengqiu Li
- School of Pharmacy
- Jinan University
- Guangzhou City Key Laboratory of Precision Chemical Drug Development
- International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development
- Ministry of Education (MOE) of People's Republic of China
| |
Collapse
|
14
|
Dissection of Protein Kinase Pathways in Live Cells Using Photoluminescent Probes: Surveillance or Interrogation? CHEMOSENSORS 2018. [DOI: 10.3390/chemosensors6020019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Chen J, Wang X, He F, Pan Z. Development of a Selective Labeling Probe for Bruton's Tyrosine Kinase Quantification in Live Cells. Bioconjug Chem 2018; 29:1640-1645. [PMID: 29652138 DOI: 10.1021/acs.bioconjchem.8b00137] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
As a key regulator of the B-cell receptor signaling pathway, Bruton's tyrosine kinase (Btk) has emerged as an important therapeutic target for various malignancies and autoimmune disorders. However, data on the expression profiles of Btk are lacking. Here, we report the discovery of a new, selective Btk probe and of a sandwich-type ELISA quantification method to detect endogenous Btk in live cells. We achieved selective labeling of Btk in vivo and quantified Btk levels in seven types of human lymphoma cell lines. This quantification method provides a powerful tool to study Btk in live cells that may also be useful in clinical settings.
Collapse
Affiliation(s)
- Jiahui Chen
- State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School , Peking University , Xili University Town, PKU Campus, Shenzhen 518055 , China
| | - Xiafeng Wang
- State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School , Peking University , Xili University Town, PKU Campus, Shenzhen 518055 , China
| | - Fengli He
- State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School , Peking University , Xili University Town, PKU Campus, Shenzhen 518055 , China
| | - Zhengying Pan
- State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School , Peking University , Xili University Town, PKU Campus, Shenzhen 518055 , China
| |
Collapse
|
16
|
Vinegoni C, Fumene Feruglio P, Brand C, Lee S, Nibbs AE, Stapleton S, Shah S, Gryczynski I, Reiner T, Mazitschek R, Weissleder R. Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging. Nat Protoc 2017; 12:1472-1497. [PMID: 28686582 PMCID: PMC5928516 DOI: 10.1038/nprot.2017.043] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The ability to directly image and quantify drug-target engagement and drug distribution with subcellular resolution in live cells and whole organisms is a prerequisite to establishing accurate models of the kinetics and dynamics of drug action. Such methods would thus have far-reaching applications in drug development and molecular pharmacology. We recently presented one such technique based on fluorescence anisotropy, a spectroscopic method based on polarization light analysis and capable of measuring the binding interaction between molecules. Our technique allows the direct characterization of target engagement of fluorescently labeled drugs, using fluorophores with a fluorescence lifetime larger than the rotational correlation of the bound complex. Here we describe an optimized protocol for simultaneous dual-channel two-photon fluorescence anisotropy microscopy acquisition to perform drug-target measurements. We also provide the necessary software to implement stream processing to visualize images and to calculate quantitative parameters. The assembly and characterization part of the protocol can be implemented in 1 d. Sample preparation, characterization and imaging of drug binding can be completed in 2 d. Although currently adapted to an Olympus FV1000MPE microscope, the protocol can be extended to other commercial or custom-built microscopes.
Collapse
Affiliation(s)
- Claudio Vinegoni
- Center for System Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Paolo Fumene Feruglio
- Center for System Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
- Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy
| | - Christian Brand
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Sungon Lee
- Center for System Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
- School of Electrical Engineering, Hanyang University, Ansan, Republic of Korea
| | - Antoinette E Nibbs
- Center for System Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Shawn Stapleton
- Center for System Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Sunil Shah
- Institute for Molecular Medicine, University of North Texas Health Science Center, Fort Worth, Texas, USA
| | - Ignacy Gryczynski
- Institute for Molecular Medicine, University of North Texas Health Science Center, Fort Worth, Texas, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Ralph Mazitschek
- Center for System Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Ralph Weissleder
- Center for System Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
17
|
Miller MA, Weissleder R. Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev 2017; 113:61-86. [PMID: 27266447 PMCID: PMC5136524 DOI: 10.1016/j.addr.2016.05.023] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 05/25/2016] [Indexed: 12/15/2022]
Abstract
Therapeutic nanoparticles (NPs) can deliver cytotoxic chemotherapeutics and other drugs more safely and efficiently to patients; furthermore, selective delivery to target tissues can theoretically be accomplished actively through coating NPs with molecular ligands, and passively through exploiting physiological "enhanced permeability and retention" features. However, clinical trial results have been mixed in showing improved efficacy with drug nanoencapsulation, largely due to heterogeneous NP accumulation at target sites across patients. Thus, a clear need exists to better understand why many NP strategies fail in vivo and not result in significantly improved tumor uptake or therapeutic response. Multicolor in vivo confocal fluorescence imaging (intravital microscopy; IVM) enables integrated pharmacokinetic and pharmacodynamic (PK/PD) measurement at the single-cell level, and has helped answer key questions regarding the biological mechanisms of in vivo NP behavior. This review summarizes progress to date and also describes useful technical strategies for successful IVM experimentation.
Collapse
Affiliation(s)
- Miles A Miller
- Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, Boston, MA 02114, USA
| | - Ralph Weissleder
- Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge St, Boston, MA 02114, USA; Department of Systems Biology, Harvard Medical School, 200 Longwood Ave, Boston, MA 02115, USA.
| |
Collapse
|
18
|
Mikula H, Stapleton S, Kohler RH, Vinegoni C, Weissleder R. Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging. Am J Cancer Res 2017; 7:1257-1265. [PMID: 28435463 PMCID: PMC5399591 DOI: 10.7150/thno.18238] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Accepted: 12/17/2016] [Indexed: 12/30/2022] Open
Abstract
Herein we describe fluorescent derivatives of vemurafenib to probe therapeutic BRAF inhibition in live cells and in vivo. The compounds were evaluated and compared by determining target binding, inhibition of mutant BRAF melanoma cell lines and live cell imaging. We show that vemurafenib-BODIPY is a superior imaging drug to visualize the targets of vemurafenib in live cells and in vivo in non-resistant and resistant melanoma tumors.
Collapse
|
19
|
Dubach JM, Kim E, Yang K, Cuccarese M, Giedt RJ, Meimetis LG, Vinegoni C, Weissleder R. Quantitating drug-target engagement in single cells in vitro and in vivo. Nat Chem Biol 2016; 13:168-173. [PMID: 27918558 DOI: 10.1038/nchembio.2248] [Citation(s) in RCA: 64] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Accepted: 09/22/2016] [Indexed: 12/24/2022]
Abstract
Quantitation of drug target engagement in single cells has proven to be difficult, often leaving unanswered questions in the drug development process. We found that intracellular target engagement of unlabeled new therapeutics can be quantitated using polarized microscopy combined with competitive binding of matched fluorescent companion imaging probes. We quantitated the dynamics of target engagement of covalent BTK inhibitors, as well as reversible PARP inhibitors, in populations of single cells using a single companion imaging probe for each target. We then determined average in vivo tumor concentrations and found marked population heterogeneity following systemic delivery, revealing single cells with low target occupancy at high average target engagement in vivo.
Collapse
Affiliation(s)
- J Matthew Dubach
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Eunha Kim
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Katherine Yang
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Michael Cuccarese
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Randy J Giedt
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Labros G Meimetis
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Claudio Vinegoni
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Ralph Weissleder
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.,Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
20
|
Haydl AM, Hilpert LJ, Breit B. Regioconvergent and Enantioselective Rhodium-Catalyzed Hydroamination of Internal and Terminal Alkynes: A Highly Flexible Access to Chiral Pyrazoles. Chemistry 2016; 22:6547-51. [DOI: 10.1002/chem.201601198] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Indexed: 11/09/2022]
Affiliation(s)
- Alexander M. Haydl
- Institut für Organische Chemie; Albert-Ludwigs-Universität Freiburg; Albertstrasse 21 79104 Freiburg im Breisgau Germany
| | - Lukas J. Hilpert
- Institut für Organische Chemie; Albert-Ludwigs-Universität Freiburg; Albertstrasse 21 79104 Freiburg im Breisgau Germany
| | - Bernhard Breit
- Institut für Organische Chemie; Albert-Ludwigs-Universität Freiburg; Albertstrasse 21 79104 Freiburg im Breisgau Germany
| |
Collapse
|
21
|
Ha Y, Choi HK. Recent conjugation strategies of small organic fluorophores and ligands for cancer-specific bioimaging. Chem Biol Interact 2016; 248:36-51. [DOI: 10.1016/j.cbi.2016.02.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 02/02/2016] [Accepted: 02/08/2016] [Indexed: 01/03/2023]
|
22
|
A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase. Sci Rep 2015; 5:16136. [PMID: 26531233 PMCID: PMC4648318 DOI: 10.1038/srep16136] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2015] [Accepted: 09/02/2015] [Indexed: 12/21/2022] Open
Abstract
As a critical regulator of the B-cell receptor signaling pathway, Bruton’s
tyrosine kinase (Btk) has attracted intensive drug discovery efforts for treating
B-cell lineage cancers and autoimmune disorders. In particular, covalent inhibitors
targeting Cys481 in Btk have demonstrated impressive clinical benefits, and their
companion affinity probes have been crucial in the drug development process.
Recently, we have discovered a novel series of 2,5-diaminopyrimidine-based covalent
irreversible inhibitors of Btk. Here, we present the discovery of a novel affinity
Btk probe based on the aforementioned scaffold and demonstrate its usage in
evaluating the target engagement of Btk inhibitors in live cells.
Collapse
|
23
|
Miller MA, Zheng YR, Gadde S, Pfirschke C, Zope H, Engblom C, Kohler RH, Iwamoto Y, Yang KS, Askevold B, Kolishetti N, Pittet M, Lippard SJ, Farokhzad OC, Weissleder R. Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug. Nat Commun 2015; 6:8692. [PMID: 26503691 PMCID: PMC4711745 DOI: 10.1038/ncomms9692] [Citation(s) in RCA: 319] [Impact Index Per Article: 35.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2014] [Accepted: 09/22/2015] [Indexed: 12/24/2022] Open
Abstract
Therapeutic nanoparticles (TNPs) aim to deliver drugs more safely and effectively to cancers, yet clinical results have been unpredictable owing to limited in vivo understanding. Here we use single-cell imaging of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneous behaviour. Model TNPs comprising a fluorescent platinum(IV) pro-drug and a clinically tested polymer platform (PLGA-b-PEG) promote long drug circulation and alter accumulation by directing cellular uptake toward tumour-associated macrophages (TAMs). Simultaneous imaging of TNP vehicle, its drug payload and single-cell DNA damage response reveals that TAMs serve as a local drug depot that accumulates significant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells. Correspondingly, TAM depletion reduces intratumoral TNP accumulation and efficacy. Thus, nanotherapeutics co-opt TAMs for drug delivery, which has implications for TNP design and for selecting patients into trials.
Collapse
Affiliation(s)
- Miles A Miller
- Center for Systems Biology, Massachusetts General Hospital (MGH), Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA
| | - Yao-Rong Zheng
- Department of Chemistry, Massachusetts Institute of Technology (MIT), 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
| | - Suresh Gadde
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital (BWH), Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
| | - Christina Pfirschke
- Center for Systems Biology, Massachusetts General Hospital (MGH), Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA
| | - Harshal Zope
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital (BWH), Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
| | - Camilla Engblom
- Center for Systems Biology, Massachusetts General Hospital (MGH), Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA
| | - Rainer H Kohler
- Center for Systems Biology, Massachusetts General Hospital (MGH), Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA
| | - Yoshiko Iwamoto
- Center for Systems Biology, Massachusetts General Hospital (MGH), Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA
| | - Katherine S Yang
- Center for Systems Biology, Massachusetts General Hospital (MGH), Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA
| | - Bjorn Askevold
- Center for Systems Biology, Massachusetts General Hospital (MGH), Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA
| | - Nagesh Kolishetti
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital (BWH), Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
| | - Mikael Pittet
- Center for Systems Biology, Massachusetts General Hospital (MGH), Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA
| | - Stephen J Lippard
- Department of Chemistry, Massachusetts Institute of Technology (MIT), 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
| | - Omid C Farokhzad
- Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital (BWH), Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA.,King Abdulaziz University, Jeddah, Saudi Arabia
| | - Ralph Weissleder
- Center for Systems Biology, Massachusetts General Hospital (MGH), Harvard Medical School, 185 Cambridge Street, Boston, Massachusetts 02114, USA.,Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Boston, Massachusetts 02115, USA
| |
Collapse
|
24
|
Kim E, Yang KS, Kohler RH, Dubach JM, Mikula H, Weissleder R. Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression. Bioconjug Chem 2015; 26:1513-8. [PMID: 26017814 DOI: 10.1021/acs.bioconjchem.5b00152] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Bruton's tyrosine kinase (Btk) is intricately involved in anti-apoptotic signaling pathways in cancer and in regulating innate immune response. A number of Btk inhibitors are in development for use in treating B-cell malignancies and certain immunologic diseases. To develop robust companion imaging diagnostics for in vivo use, we set out to explore the effects of red wavelength fluorochrome modifications of two highly potent irreversible Btk inhibitors, Ibrutinib and AVL-292. Surprisingly, we found that subtle chemical differences in the fluorochrome had considerable effects on target localization. Based on iterative designs, we developed a single optimized version with superb in vivo imaging characteristics enabling single cell Btk imaging in vivo. This agent (Ibrutinib-SiR-COOH) is expected to be a valuable chemical tool in deciphering Btk biology in cancer and host cells in vivo.
Collapse
Affiliation(s)
- Eunha Kim
- †Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, Massachusetts 02114, United States
| | - Katherine S Yang
- †Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, Massachusetts 02114, United States
| | - Rainer H Kohler
- †Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, Massachusetts 02114, United States
| | - John M Dubach
- †Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, Massachusetts 02114, United States
| | - Hannes Mikula
- †Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, Massachusetts 02114, United States
| | - Ralph Weissleder
- †Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, Massachusetts 02114, United States.,‡Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Boston, Massachusetts 02115, United States
| |
Collapse
|
25
|
Haydl AM, Xu K, Breit B. Regio- and Enantioselective Synthesis of N-Substituted Pyrazoles by Rhodium-Catalyzed Asymmetric Addition to Allenes. Angew Chem Int Ed Engl 2015; 54:7149-53. [DOI: 10.1002/anie.201501758] [Citation(s) in RCA: 81] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Indexed: 01/06/2023]
|
26
|
Haydl AM, Xu K, Breit B. Regio- and Enantioselective Synthesis of N-Substituted Pyrazoles by Rhodium-Catalyzed Asymmetric Addition to Allenes. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201501758] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
27
|
Turetsky A, Lee K, Song J, Giedt RJ, Kim E, Kovach AE, Hochberg EP, Castro CM, Lee H, Weissleder R. On chip analysis of CNS lymphoma in cerebrospinal fluid. Am J Cancer Res 2015; 5:796-804. [PMID: 26000053 PMCID: PMC4440438 DOI: 10.7150/thno.11220] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Accepted: 03/02/2015] [Indexed: 12/11/2022] Open
Abstract
Molecular profiling of central nervous system lymphomas in cerebrospinal fluid (CSF) samples can be challenging due to the paucicellular and limited nature of the samples. Presented herein is a microfluidic platform for complete CSF lymphoid cell analysis, including single cell capture in sub-nanoliter traps, and molecular and chemotherapeutic response profiling via on-chip imaging, all in less than one hour. The system can detect scant lymphoma cells and quantitate their kappa/lambda immunoglobulin light chain restriction patterns. The approach can be further customized for measurement of additional biomarkers, such as those for differential diagnosis of lymphoma subtypes or for prognosis, as well as for imaging exposure to experimental drugs.
Collapse
|
28
|
Liu N, Hoogendoorn S, van de Kar B, Kaptein A, Barf T, Driessen C, Filippov DV, van der Marel GA, van der Stelt M, Overkleeft HS. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. Org Biomol Chem 2015; 13:5147-57. [DOI: 10.1039/c5ob00474h] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Direct and two-step activity-based probes allow for profiling of Bruton's tyrosine kinase in vitro and in situ.
Collapse
Affiliation(s)
- Nora Liu
- Leiden Institute of Chemistry
- Leiden University
- 2300 RA Leiden
- The Netherlands
| | - Sascha Hoogendoorn
- Leiden Institute of Chemistry
- Leiden University
- 2300 RA Leiden
- The Netherlands
| | | | | | | | | | - Dmitri V. Filippov
- Leiden Institute of Chemistry
- Leiden University
- 2300 RA Leiden
- The Netherlands
| | | | | | | |
Collapse
|
29
|
Zhang Q, Liu H, Pan Z. A general approach for the development of fluorogenic probes suitable for no-wash imaging of kinases in live cells. Chem Commun (Camb) 2014; 50:15319-22. [DOI: 10.1039/c4cc07429g] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A general approach is presented for developing small molecule-based fluorogenic probes suitable for no-wash imaging of endogenous kinases in live cells.
Collapse
Affiliation(s)
- Qing Zhang
- Key Laboratory of Chemical Genomics
- Key Laboratory of Structural Biology
- School of Chemical Biology and Biotechnology Shenzhen Graduate School
- Peking University Xili University Town
- Shenzhen, 518055 China
| | - Hui Liu
- Key Laboratory of Chemical Genomics
- Key Laboratory of Structural Biology
- School of Chemical Biology and Biotechnology Shenzhen Graduate School
- Peking University Xili University Town
- Shenzhen, 518055 China
| | - Zhengying Pan
- Key Laboratory of Chemical Genomics
- Key Laboratory of Structural Biology
- School of Chemical Biology and Biotechnology Shenzhen Graduate School
- Peking University Xili University Town
- Shenzhen, 518055 China
| |
Collapse
|